Derivation and validation of a new visceral adiposity index for predicting visceral obesity and cardiometabolic risk in a Korean population

PloS One
Sung-Kwan OhJi-Won Lee

Abstract

The visceral adiposity index (VAI), an indirect marker of visceral adipose tissue, serves as a model associated with cardiometabolic risk, but has limitations regarding the Asian population. We sought to develop a new VAI (NVAI) for the Korean population and compare it to VAI for prediction of atherosclerotic cardiovascular disease (ASCVD) risk and development of major cardiovascular diseases (CVD) and stroke. Patients (969) who underwent visceral fat area measurement were analyzed. After exclusion, 539 patients (142 men, 397 women) were randomly divided into internal (n = 374) and external validation (n = 165) data set. The NVAI was developed using univariate and multivariate logistic regression with backward selection of predictors. Receiver operating characteristic (ROC) curve analysis and comparison of the area under the curve (AUC) verified the better predictor of ASCVD risk score. Additionally, nationwide population-based cross-sectional survey data (Korean National Health and Nutrition Examination Survey [KNHANES] 2008-2010, n = 29,235) was used to validate the NVAI's ability to predict ASCVD risk and major CVD and stroke. The NVAI better reflected visceral fat area in internal and external data sets, with AUCs of 0.911 ...Continue Reading

References

Nov 1, 1983·The Journal of Clinical Investigation·E FerranniniR A DeFronzo
Sep 1, 1983·The Journal of Clinical Investigation·M KrotkiewskiU Smith
Apr 1, 1984·The American Journal of Clinical Nutrition·W O GrauerH I Goldberg
Mar 1, 1995·American Journal of Hypertension·A MoanS E Kjeldsen
Dec 15, 1996·American Journal of Epidemiology·S P WalkerW C Willett
Dec 20, 2002·Obesity Research·Alessandra Nunes FariaMaria Teresa Zanella
May 1, 1993·Obesity Research·P Björntorp
Jun 1, 2006·Diabetes Research and Clinical Practice·Sang Yeoup LeeHyung Joon Yoo
Oct 17, 2006·Journal of Internal Medicine·M LuE Weiderpass
Dec 15, 2006·Nature·Luc F Van GaalChristophe E De Block
Dec 15, 2006·Nature·Jean-Pierre Després, Isabelle Lemieux
Mar 22, 2008·Arteriosclerosis, Thrombosis, and Vascular Biology·Jean-Pierre DesprésPaul Poirier
Dec 4, 2008·The Journal of Clinical Endocrinology and Metabolism·Michael D Jensen
Nov 23, 2011·Expert Review of Cardiovascular Therapy·Caroline RhéaumePaul Poirier
Mar 8, 2012·Cardiovascular Diabetology·Bozorgmanesh MohammadrezaAzizi Fereidoun Fereidoun Prof
Apr 18, 2012·The Journal of Clinical Endocrinology and Metabolism·Mark Hamer, Emmanuel Stamatakis
Sep 6, 2012·Circulation·Jean-Pierre Després
Dec 26, 2012·Angiology·Mariusz StepienJacek Rysz
Jul 17, 2013·Applied Physiology, Nutrition, and Metabolism = Physiologie Appliquée, Nutrition Et Métabolisme·Belinda ElishaRémi Rabasa-Lhoret
Nov 14, 2013·Journal of the American Pharmacists Association : JAPhA
Jul 30, 2014·World Journal of Radiology·Miwa RyoIichiro Shimomura
Jan 27, 2017·Circulation·Emelia J BenjaminUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Mar 10, 2018·Hormone Molecular Biology and Clinical Investigation·Susan Sam

❮ Previous
Next ❯

Citations

Feb 14, 2020·International Journal of Environmental Research and Public Health·Xiue GaoBo Chen
Apr 9, 2021·Journal of Endocrinological Investigation·K FanZ Mao
May 13, 2021·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·Da-Hye SonHyuk-Jae Chang

❮ Previous
Next ❯

Software Mentioned

R
R package
SPSS
NVAI

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.